Cargando…
Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial)
BACKGROUND: Neoadjuvant chemotherapy (nCT) has been the recommended treatment for locally advanced esophageal squamous cell carcinoma (ESCC). The addition of programmed cell death protein 1 (PD-1) inhibitor to nCT may improve oncologic outcome and survival. However, high-level evidence of neoadjuvan...
Autores principales: | Yin, Jun, Lin, Siyun, Fang, Yong, Jiao, Heng, Chen, Zongwei, Tang, Han, Gu, Jianmin, Zhang, Shaoyuan, Sun, Linyi, Li, Yin, Han, Yongtao, Chen, Qixun, Chen, Haiquan, Li, Zhigang, Tan, Lijie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992557/ https://www.ncbi.nlm.nih.gov/pubmed/36910109 http://dx.doi.org/10.21037/jtd-22-1789 |
Ejemplares similares
-
Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin
por: De Lorenzo, C, et al.
Publicado: (2007) -
DJ‐1 depletion prevents immunoaging in T‐cell compartments
por: Zeng, Ni, et al.
Publicado: (2022) -
Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
por: Yin, Jun, et al.
Publicado: (2023) -
Publisher Correction: Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
por: Yin, Jun, et al.
Publicado: (2023) -
IMMUNOAGING – THE EFFECT OF AGE ON SERUM LEVELS OF NET BIOMARKERS IN MEN: A PILOT STUDY
por: Garley, Marzena, et al.
Publicado: (2023)